Valeant posts 3Q gains; Allergan attacks numbers
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals reported sales and profit gains for the third quarter of 2014 and Valeant's reluctant acquisition target Allergan immediately called the quarterly update into question.